Endocrinology in the time of COVID-19: Management of calcium metabolic disorders and osteoporosis

Research output: Contribution to journalArticlepeer-review

Standard

Endocrinology in the time of COVID-19 : Management of calcium metabolic disorders and osteoporosis. / Gittoes, Neil; Criseno, Sherwin; Appelman-Dijkstra, Natasha; Bollerslev, Jens; Canalis, Ernesto; Rejnmark, Lars; Hassan-Smith, Zaki.

In: European Journal of Endocrinology, Vol. 183, No. 2, 08.2020, p. G57-G65.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Gittoes, Neil ; Criseno, Sherwin ; Appelman-Dijkstra, Natasha ; Bollerslev, Jens ; Canalis, Ernesto ; Rejnmark, Lars ; Hassan-Smith, Zaki. / Endocrinology in the time of COVID-19 : Management of calcium metabolic disorders and osteoporosis. In: European Journal of Endocrinology. 2020 ; Vol. 183, No. 2. pp. G57-G65.

Bibtex

@article{705b100674144298be16c28a82bb2a1b,
title = "Endocrinology in the time of COVID-19: Management of calcium metabolic disorders and osteoporosis",
abstract = "Endocrinologists have had to make rapid changes to services so that resources can be focused on the COVID-19 response to help prevent spread of the virus. Herein we provide pragmatic advice on the management of commonly encountered calcium metabolic problems and osteoporosis. Non-urgent elective appointments should be postponed, and remote consultations and digital health solutions promoted. Patients should be empowered to self-manage their conditions safely. Patients, their caregivers and healthcare providers should be directed to assured national or international online resources and specific patient groups. For patients in acute hospital settings, existing emergencyguidance on the management of hyper- and hypo-calcaemia should be followed. An approach to osteoporosis management is outlined. IV zoledronic acid infusions can be delayed for 6–9 months during the pandemic. Patients established on denosumab, teriparatide and abaloparatide should continue planned therapy. In the event of supply issues with teriparatide or abaloparatide, pausing this treatment in the short term is likely to be relatively harmless,whereas delaying denosumab may cause an immediate increased risk of fracture. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use ofresources and resilience of healthcare systems in its aftermath.",
author = "Neil Gittoes and Sherwin Criseno and Natasha Appelman-Dijkstra and Jens Bollerslev and Ernesto Canalis and Lars Rejnmark and Zaki Hassan-Smith",
note = "Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.",
year = "2020",
month = aug,
doi = "10.1530/EJE-20-0385",
language = "English",
volume = "183",
pages = "G57--G65",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica",
number = "2",

}

RIS

TY - JOUR

T1 - Endocrinology in the time of COVID-19

T2 - Management of calcium metabolic disorders and osteoporosis

AU - Gittoes, Neil

AU - Criseno, Sherwin

AU - Appelman-Dijkstra, Natasha

AU - Bollerslev, Jens

AU - Canalis, Ernesto

AU - Rejnmark, Lars

AU - Hassan-Smith, Zaki

N1 - Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

PY - 2020/8

Y1 - 2020/8

N2 - Endocrinologists have had to make rapid changes to services so that resources can be focused on the COVID-19 response to help prevent spread of the virus. Herein we provide pragmatic advice on the management of commonly encountered calcium metabolic problems and osteoporosis. Non-urgent elective appointments should be postponed, and remote consultations and digital health solutions promoted. Patients should be empowered to self-manage their conditions safely. Patients, their caregivers and healthcare providers should be directed to assured national or international online resources and specific patient groups. For patients in acute hospital settings, existing emergencyguidance on the management of hyper- and hypo-calcaemia should be followed. An approach to osteoporosis management is outlined. IV zoledronic acid infusions can be delayed for 6–9 months during the pandemic. Patients established on denosumab, teriparatide and abaloparatide should continue planned therapy. In the event of supply issues with teriparatide or abaloparatide, pausing this treatment in the short term is likely to be relatively harmless,whereas delaying denosumab may cause an immediate increased risk of fracture. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use ofresources and resilience of healthcare systems in its aftermath.

AB - Endocrinologists have had to make rapid changes to services so that resources can be focused on the COVID-19 response to help prevent spread of the virus. Herein we provide pragmatic advice on the management of commonly encountered calcium metabolic problems and osteoporosis. Non-urgent elective appointments should be postponed, and remote consultations and digital health solutions promoted. Patients should be empowered to self-manage their conditions safely. Patients, their caregivers and healthcare providers should be directed to assured national or international online resources and specific patient groups. For patients in acute hospital settings, existing emergencyguidance on the management of hyper- and hypo-calcaemia should be followed. An approach to osteoporosis management is outlined. IV zoledronic acid infusions can be delayed for 6–9 months during the pandemic. Patients established on denosumab, teriparatide and abaloparatide should continue planned therapy. In the event of supply issues with teriparatide or abaloparatide, pausing this treatment in the short term is likely to be relatively harmless,whereas delaying denosumab may cause an immediate increased risk of fracture. The challenge of this pandemic will act as a catalyst to innovate within our management of metabolic bone and mineral disorders to ensure best use ofresources and resilience of healthcare systems in its aftermath.

U2 - 10.1530/EJE-20-0385

DO - 10.1530/EJE-20-0385

M3 - Article

VL - 183

SP - G57-G65

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -